Concerns Raised About Patient-Reported Outcomes in CheckMate 214 Trial
An exploratory analysis showed that patients who received nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up?
Source: CancerNetwork - Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
More News: Cancer & Oncology | Yervoy